Evidence map›Paper›PMID 35699985›Full record

ArticleJMIR cancer2022

Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis.

Jyoti Chauhan, Sathyaraj Aasaithambi, Iván Márquez-Rodas, Luigi Formisano, Sophie Papa, Nicolas Meyer, Andrea Forschner, Guy Faust, Mike Lau, Alexandros Sagkriotis

Open access · goldAbstract read
In one paragraph

Article in JMIR cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 7 countries.

Jyoti ChauhanNovartis Healthcare Pvt Ltd, Hyderabad, India.ORCID https://orcid.org/0000-0002-7115-1709
Sathyaraj AasaithambiNovartis Healthcare Pvt Ltd, Hyderabad, India.ORCID https://orcid.org/0000-0001-9264-0846
Iván Márquez-RodasDepartment of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID https://orcid.org/0000-0002-2476-668X
Luigi FormisanoDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.ORCID https://orcid.org/0000-0001-7205-5105
Sophie PapaSchool of Cancer and Pharmaceutical Studies, King's College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-9063-7675
Nicolas MeyerDepartment of Onco-Dermatology, Toulouse Cancer Institute, Toulouse, France.ORCID https://orcid.org/0000-0003-4519-8666
Andrea ForschnerDepartment of Dermatology, University Hospital Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0002-6185-4945
Guy FaustDepartment of Oncology, University Hospitals of Leicester, Leicester, United Kingdom.ORCID https://orcid.org/0000-0003-0864-0961
Mike LauNovartis Pharma AG, Basel, Switzerland.ORCID https://orcid.org/0000-0001-5076-3944
Alexandros SagkriotisNovartis Pharma AG, Basel, Switzerland.ORCID https://orcid.org/0000-0002-1666-5248
Novartis (India) · INNovartis (Switzerland) · CHHospital General Universitario Gregorio Marañón · ESKing's College London · GBUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversity Children's Hospital Tübingen · DEUniversity Hospitals of Leicester NHS Trust · GBUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCutaneous melanoma is an aggressive malignancy that is proposed to account for 90% of skin cancer-related mortality. Individuals with melanoma experience both physical and psychological impacts associated with their diagnosis and treatment. Health-related information is being increasingly accessed and shared by stakeholders on social media platforms.

objectiveThis study aimed to assess how individuals living with melanoma across 14 European countries use social media to discuss their needs and provide their perceptions of the disease.

methodsSocial media sources including Twitter, forums, and blogs were searched using predefined search strings of keywords relating to melanoma. Manual and automated relevancy approaches filtered the extracted data for content that provided patient-centric insights. This contextualized data was then mined for insightful concepts around the symptoms, diagnosis, treatment, impacts, and lived experiences of melanoma.

resultsA total of 182,400 posts related to melanoma were identified between November 2018 and November 2020. Following exclusion of irrelevant posts and using random sampling methodology, 864 posts were identified as relevant to the study objectives. Of the social media channels included, Twitter was the most commonly used, followed by forums and blogs. Most posts originated from the United Kingdom (n=328, 38%) and Spain (n=138, 16%). Of the relevant posts, 62% (n=536) were categorized as originating from individuals with melanoma. The most frequently discussed melanoma-related topics were treatment (436/792, 55%), diagnosis and tests (261/792, 33%), and remission (190/792, 24%). The majority of treatment discussions were about surgery (292/436, 67%), followed by immunotherapy (52/436, 12%). In total, 255 posts discussed the impacts of melanoma, which included emotional burden (n=179, 70%), physical impacts (n=61, 24%), effects on social life (n=43, 17%), and financial impacts (n=10, 4%).

conclusionsFindings from this study highlight how melanoma stakeholders discuss key concepts associated with the condition on social media, adding to the conceptual model of the patient journey. This social media listening approach is a powerful tool for exploring melanoma stakeholder perspectives, providing insights that can be used to corroborate existing data and inform future studies.

Indexed as

cancerhealth informationmelanomamortality ratepatient journeyreal-world evidencesocial mediasocial media listening

Identifiers

PMID35699985
PMCPMC9237767
OpenAlexW4225860173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.